Obicetrapib safety analysis: Pooled phase 3 clinical trial experience
American Journal of Preventive Cardiology · 2026-08 · 28 · 101547
DOI: 10.1016/j.ajpc.2026.101547 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Preventive Cardiology, 2026-08. Verfasst von Adam J Nelson und 11 weiteren Autor:innen. Beteiligte Einrichtung: Victorian Heart Institute, Monash University, Clayton, Australia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NewAmsterdam Pharma.
Abstract (Originalsprache)
Background
Obicetrapib is a potent, selective cholesteryl ester transfer protein (CETP) inhibitor that lowers LDL-C and raises HDL-C. Although prior studies have demonstrated efficacy and general tolerability, a comprehensive evaluation of its safety profile across later-stage clinical trials is needed.
Methods
Safety outcomes were assessed in a pooled analysis of two phase III trials comparing obicetrapib 10 mg daily with placebo in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Participants received treatment for 365 days. Safety endpoints included treatment-emergent adverse events (TEAEs) and prespecified events of special interest including hepatic, muscular, glycemic, renal and ocular parameters as well as overall rates of discontinuation.
Results
A total of 2,880 participants were included (mean age 64 years; 36 % female; 82 % with ASCVD; 35.8 % with diabetes). Overall TEAE rates were similar between obicetrapib and placebo (60.2 % vs 62.0 %). AEs leading to treatment discontinuation occurred in 4.1 % of obicetrapib-treated participants and 5.3 % on placebo, Risk Ratio (RR) 0.77 [0.54-1.08]. No clinically significant change in blood pressure was observed between groups and hypertension events were comparable. There was no difference between the groups in liver or muscle-related endpoints. Reduction in eGFR occurred less often with obicetrapib ( compared to placebo (6.7 % vs. 8.7 % RR 0.77 [0.59, 1.00])). Macular degeneration was reported once in the obicetrapib group (n= 1 [0.1 %]). Deaths were similar between treatment groups. No new safety signals were identified.
Conclusions
Obicetrapib demonstrated a favorable safety profile over 12 months, with AE rates comparable to placebo. These findings extend our understanding of the safety and tolerability of obicetrapib.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Victorian Heart Institute, Monash University, Clayton, Australia.
- NewAmsterdam Pharma, Amsterdam, Netherlands.
- University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
- Imperial College, London, United Kingdom.
Förderung
- NewAmsterdam Pharma
Zitieren
APA
Nelson, A. J., Kastelein, J. J., Ditmarsch, M., Hall, C., Kling, D., Ortiz, N., Wicks, D. L., Hsieh, A., Szarek, M., Ray, K. K., Davidson, M. H., & Nicholls, S. J. (2026). Obicetrapib safety analysis: Pooled phase 3 clinical trial experience. American Journal of Preventive Cardiology, 28, 101547. https://doi.org/10.1016/j.ajpc.2026.101547
Vancouver
Nelson AJ, Kastelein JJ, Ditmarsch M, Hall C, Kling D, Ortiz N, et al. Obicetrapib safety analysis: Pooled phase 3 clinical trial experience. American Journal of Preventive Cardiology. 2026;28:101547. doi:10.1016/j.ajpc.2026.101547
BibTeX
@article{Nelson2026,
author = {Nelson, Adam J and Kastelein, John Jp and Ditmarsch, Marc and Hall, Collette and Kling, Douglas and Ortiz, Nancy and Wicks, Douglas L and Hsieh, Andrew and Szarek, Michael and Ray, Kausik K and Davidson, Michael H and Nicholls, Stephen J},
title = {Obicetrapib safety analysis: Pooled phase 3 clinical trial experience},
journal = {American Journal of Preventive Cardiology},
year = {2026},
volume = {28},
pages = {101547},
doi = {10.1016/j.ajpc.2026.101547}
}
EUVIMED